Narcolepsy type 1 is caused by autoimmune destruction of ~70,000 orexin/hypocretin-producing neurons in the lateral hypothalamus. Strongly associated with HLA-DQB1*06:02. Once these neurons die, the body loses its only source of orexin — the neuropeptide that stabilises wakefulness, prevents inappropriate REM intrusion, and regulates sleep-wake transitions.
Orexin receptors (OX1R and OX2R) are distributed throughout the brain — in the locus coeruleus, tuberomammillary nucleus, dorsal raphe, and cortex. These receptors remain structurally intact and fully functional even after years of orexin deficiency. The hardware is fine. It just has no signal.
Don't try to replace the dead neurons. Instead, make other neurons produce orexin ectopically. The hSyn promoter restricts expression to neurons only (no glia, no peripheral tissue). AAV9 crosses the blood-brain barrier and transduces CNS neurons broadly. The codon-optimised HCRT transgene encodes prepro-orexin, which is cleaved into Orexin-A (33 amino acids) and Orexin-B (28 amino acids).
Single injection → AAV9 transduces neurons → stable episomal expression of orexin → downstream receptors activated → wakefulness stabilised, cataplexy eliminated, REM normalised. AAV episomes persist for the life of post-mitotic neurons. One shot, permanent cure.
"Ectopic orexin production anywhere in the brain completely rescues the narcolepsy phenotype in knockout mice." The orexin does not need to come from the lateral hypothalamus. Any neuron will do.
AAV-delivered orexin gene restored 48% longer wake bouts and normalised REM sleep timing in narcoleptic mice. Demonstrated that viral vector delivery is a viable therapeutic approach.
OX1R and OX2R remain functionally intact in narcolepsy patients, even decades after orexin neuron loss. This is confirmed by the efficacy of suvorexant (dual orexin receptor antagonist) in healthy subjects — blocking the same receptors causes narcolepsy-like symptoms, proving they work. The signalling infrastructure is preserved. It only needs the ligand.
Injection into cerebrospinal fluid at the lumbar puncture site. CSF circulation carries AAV9 rostrally to the brain. Standard clinical procedure performed under local anaesthesia. Well-established route for CNS gene therapies (Zolgensma uses similar approach).
STANDARD CLINICALVia the olfactory pathway. AAV9 bypasses the blood-brain barrier through the cribriform plate, reaching the olfactory bulb and then the hypothalamus. Non-invasive administration. Currently experimental but promising preclinical data in rodent models.
EXPERIMENTALVectorBuilder custom AAV production quote
Pharmacological stack while awaiting gene therapy